FAQ on Calidi Biotherapeutics Inc.'s Investor Webinar and Oncology Advancements

What is the main topic of the Calidi Biotherapeutics investor webinar?

The webinar will showcase Calidi’s RedTail platform, a systemically delivered viral therapy designed to treat metastatic tumors, and discuss preclinical data on lead candidate CLD-401.

When is the Calidi Biotherapeutics investor webinar taking place?

The webinar is scheduled for July 24, 2025, at 4:15 p.m. ET.

Who will lead the Calidi Biotherapeutics investor webinar?

The event will be led by CEO Eric Poma, Ph.D.

What is the RedTail platform?

The RedTail platform is a systemically delivered viral therapy designed to treat metastatic tumors by evading immune detection.

What were the results of the preclinical data on CLD-401?

Preclinical data on CLD-401 showed tumor elimination and immune memory activation.

What are Calidi Biotherapeutics’ next steps following the webinar?

The company is progressing toward an IND filing and pursuing strategic pharma partnerships to support commercialization.

Where can I find more information about Calidi Biotherapeutics?

More information is available on the company’s website at www.calidibio.com and in the company’s newsroom at https://ibn.fm/CLDI.

What is the significance of Calidi Biotherapeutics’ work in oncology?

Calidi’s work is significant because it aims to enhance the efficacy and safety of oncolytic virus therapies, potentially treating or preventing metastatic disease.

How does Calidi Biotherapeutics’ approach compare to alternatives?

Calidi’s dual approach of using stem cell-based platforms and enveloped virotherapies is designed to offer enhanced efficacy and improved patient safety compared to traditional methods.

Who should attend the Calidi Biotherapeutics investor webinar?

Investors, stakeholders, and anyone interested in advancements in oncology treatments and genetic medicine therapies should consider attending.